Form 4: Belite Bio CFO Acquires Shares

Belite Bio, Inc. reports that Chief Financial Officer Hao-Yuan Chuang acquired 10,000 ordinary shares upon the vesting of restricted stock units.

Summary

• Hao-Yuan Chuang, Chief Financial Officer and Director of Belite Bio, Inc., acquired 10,000 ordinary shares.
• The acquisition occurred on April 21, 2026, following the satisfaction of performance criteria for restricted stock units (RSUs) granted on September 15, 2025.
• Following this transaction, Mr. Chuang beneficially owns 205,264 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a standard insider transaction related to RSU vesting rather than new financial performance or strategic shifts.

Positives

• The Chief Financial Officer and Director has acquired additional shares, indicating confidence in the company.
• The vesting of RSUs suggests that performance targets set by the company have been met.

Future Outlook

No specific future outlook or guidance is provided in this filing.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of shares by a CFO, are common disclosures in the biotechnology sector and can be interpreted as a signal of management's belief in the company's prospects.

Stakeholder Impact

• Shareholders may view the CFO's acquisition of shares positively, as it can signal confidence in the company's future performance.

Key Dates

Keywords

Belite Bio, BLTE, Form 4, Insider Transaction, Stock Acquisition, Restricted Stock Units, Vesting, Chief Financial Officer, Director